on GENFIT (EPA:GNFT)
GENFIT's Shareholder Meeting Approves Board's Resolutions
On June 17, 2025, GENFIT held its Combined Shareholders Meeting where all board-recommended resolutions were approved, except for resolution n°28. The meeting saw a quorum of 27.21%. GENFIT, a key player in biopharmaceuticals, focuses on rare liver diseases. Headquartered in Lille, and with offices in Zurich and Cambridge, USA, the company is listed on Nasdaq and Euronext.
The company has a strong R&D portfolio, primarily targeting Acute-on-Chronic Liver Failure (ACLF) with five assets under development. GENFIT's expertise in molecule development has led to the approval of Iqirvo® for Primary Biliary Cholangitis.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENFIT news